X4 PHARMACEUTICALS, INC Long-Term Debt
X4 PHARMACEUTICALS, INC (XFOR) had Long-Term Debt of $54.57 million as of 2023-12-31, per its 10-K filed 2024-03-21.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt, Excluding Current Maturities
us-gaap:LongTermDebtNoncurrent · last filed 2024-03-21
- 2023-12-31: Long-term Debt, Excluding Current Maturities $54.57M.
- 2022-12-31: Long-term Debt, Excluding Current Maturities $32.30M.
- 2021-12-31: Long-term Debt, Excluding Current Maturities $33.14M.
- 2020-12-31: Long-term Debt, Excluding Current Maturities $33.18M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2023-12-31 | $54.57M 10-K · filed 2024-03-21 |
| 2022-12-31 | $32.30M 10-K · filed 2024-03-21 |
| 2021-12-31 | $33.14M 10-K · filed 2023-03-21 |
| 2020-12-31 | $33.18M 10-K · filed 2022-03-17 |
| 2019-12-31 | $20.00M 10-K · filed 2020-03-12 |
| 2019-09-30 | $20.00M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $22.20M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $14.25M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $8.31M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |